Aller au contenu
Force et musclesArticle de recherche3 min read

Weak grip strength was more common in midlife adults with bone, joint, diabetes or brain conditions

Collectif éditorial MoveVitals · Study published · Reading updated

Original paper:Sarcopenia, long-term conditions, and multimorbidity: findings from UK Biobank participants. · Journal of cachexia, sarcopenia and muscle · 2019 · Article original ↗

À retenir

Among 499,046 UK Biobank participants aged 40-70, 5.3% had probable sarcopenia (low grip strength), and people with two or more long-term conditions had nearly twice the odds (OR 1.96) of it. This is a single baseline snapshot, so it cannot show which came first, and the sample was a volunteer cohort.

Study design

Article de recherche

Reading basis

Published abstract

Reading focus

Design & applicability

Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.

Question de recherche

Sarcopenia, the loss of muscle strength and mass, becomes common with age and predicts poor outcomes, but it may appear earlier in people with long-term conditions. The authors described how common probable sarcopenia is in midlife and whether different categories of long-term conditions and multimorbidity are linked to it.

Population et méthode

Cross-sectional analysis of baseline data from 499,046 UK Biobank participants aged 40-70. The main outcome was probable sarcopenia, defined as maximum grip strength below sex-specific cut-points. Long-term conditions were recorded in an interview and sorted into categories using a hierarchy. Logistic regression estimated the association between each category and probable sarcopenia, adjusting for age, sex and body mass index (BMI), and a separate analysis examined multimorbidity (two or more long-term conditions).

Résultats

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Probable sarcopenia had an overall prevalence of 5.3% and became more common with age.
  2. 2
    The strongest links were with musculoskeletal or trauma conditions (OR 2.17, 95% CI 2.11-2.23), endocrine or diabetes conditions (OR 1.49, 95% CI 1.45-1.55) and neurological or psychiatric conditions (OR 1.39, 95% CI 1.34-1.43).
  3. 3
    44.5% of the sample had multimorbidity, and those people had nearly twice the odds of probable sarcopenia compared with those without it (OR 1.96, 95% CI 1.91-2.02).

Limites et incertitude

  1. 1
    Conditions and grip strength were recorded at one time point, so the data cannot show whether a condition led to muscle weakness or the reverse.
  2. 2
    Probable sarcopenia was defined by grip strength alone, without a muscle mass measurement, and the abstract does not say how well it matches a full diagnosis.
  3. 3
    Conditions were self-reported in an interview, and the abstract does not describe how participants were recruited or how representative they are.
  4. 4
    This reading is based on the abstract only.

Mise en perspective

Low grip strength is not just an old-age issue: in this large cohort it was more common in midlife adults with several health conditions. The authors suggest these groups may benefit from sarcopenia assessment. A reader with a long-term condition who notices weakness can bring it up with their clinician, but grip strength alone does not diagnose anything.

Vos données

Grip strength is measured with a dynamometer rather than a wrist wearable, so the closest personal data are training logs for strength work and, for a wearable, activity volume. If you have access to a grip dynamometer, use the same hand, device and time of day, and compare trends over months rather than single readings.

Comprendre ce type de preuve

The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.

Résumé structuré des auteurs English

Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.

Background

Sarcopenia, the loss of muscle strength and mass, predicts adverse outcomes and becomes common with age. There is recognition that sarcopenia may occur at younger ages in those with long-term conditions (LTCs) as well as those with multimorbidity (the presence of two or more LTCs), but their relationships have been little explored. Our aims were to describe the prevalence of sarcopenia in UK Biobank, a large sample of men and women aged 40-70 years, and to explore relationships with different categories of LTCs and multimorbidity.

Methods

We used data from 499 046 participants in the baseline of UK Biobank. Our main outcome was probable sarcopenia based on maximum grip strength below sex-specific cut-points. Participants' LTCs were recorded during an interview and categorized against a hierarchy. We used logistic regression to examine the independent associations between each category of LTCs and probable sarcopenia, including adjustment for age, sex, and body mass index. We also examined the association with multimorbidity.

Results

Probable sarcopenia had an overall prevalence of 5.3% and increased with age. The categories with the strongest associations with probable sarcopenia were musculoskeletal/trauma [OR 2.17 (95% CI: 2.11, 2.23)], endocrine/diabetes [OR 1.49 (95% CI: 1.45, 1.55)], and neurological/psychiatric [OR 1.39 (95% CI: 1.34, 1.43)] LTCs. Almost half of the sample (44.5%) had multimorbidity, and they were at nearly twice the odds of probable sarcopenia [OR 1.96 (95% CI: 1.91, 2.02)] compared with those without.

Conclusions

We have shown an overall prevalence of 5.3% of probable sarcopenia at ages 40-70 in UK Biobank. The risk of probable sarcopenia was higher in those with some categories of LTCs, suggesting that these groups may stand to benefit from assessment of sarcopenia, during mid-life as well as old age.

Sources et attribution

Sarcopenia, long-term conditions, and multimorbidity: findings from UK Biobank participants.

Dodds RM, Granic A, Robinson SM, Sayer AA.

Journal of cachexia, sarcopenia and muscle · 2019-12-30

DOI: 10.1002/jcsm.12503 ↗PubMed · 31886632 ↗Europe PMC · Licence indiquée: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée

Sources vérifiées 2026-11-01

Guides pratiques

À lire ensemble

·Synthèse de revues

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

Explications approfondiesLire l’étude →
·Méta-analyse d’essais

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

Explications approfondiesLire l’étude →
·Méta-analyse observationnelle

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

Explications approfondiesLire l’étude →
·Méta-analyse d’essais

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

Explications approfondiesLire l’étude →
Force et muscles →